Neurochem’s Supplement Launch In U.S. On Hold Due To DSHEA Question
This article was originally published in The Tan Sheet
Executive Summary
Neurochem plans to launch a failed Alzheimer's drug candidate as a dietary supplement in Canada this year and in Europe and Japan in 2009, but has not determined whether it will make the product available in theU.S., company executives said Feb. 21
You may also be interested in...
People In Brief
NCCAM advisors: The National Center for Complementary and Alternative Medicine names six members to four-year terms on its national advisory council, which meets three times a year to offer advice and recommendations on conduct, support and prioritization of CAM research. The new members are Timothy C. Birdsall, vice president for integrative medicine at the Cancer Treatment Centers of America in Zion, Ill.; Boyd W. Bowden II, on the orthopedics staff at Doctors Hospital and at Orthopedic and Neurological Consultants Inc., in Columbus, Ohio; Gert Bronfort, a professor and associate vice president of research at Northwestern Health Sciences University, Bloomington, Minn., where he is also senior clinical researcher at the Wolfe-Harris Center for Clinical Studies; Lupo T. Carlota, president and founder of the Medical Acupuncture Research Institute of America in Memphis, Tenn.; Shin Lin, a professor of developmental and cell biology, physiology and biophysics and biomedical engineering at the University of California-Irvine, and a member of the advisory board and faculty of the university's Susan Samueli Center for Integrative Medicine; and Herman A. Taylor Jr., a professor of medicine and attending physician in the Division of Cardiovascular Diseases and Internal Medicine at the University of Mississippi Medical Center in Jackson...
Neurochem Faces Obstacles To Making Supplement Out Of Drug Candidate
Neurochem's plan to market a failed Alzheimer's disease drug candidate as a dietary supplement could stumble in the United States over requirements of the Dietary Supplement Health and Education Act, regulatory experts say
OTC Prices Make PPI-Aspirin Therapy For CVD Cost-Effective – Study
Using proton pump inhibitors to prevent GI bleeding from low-dose aspirin therapy for cardiovascular health is cost-effective only at OTC prices, according to researchers